Atrion Co. (NASDAQ:ATRI) announced a quarterly dividend on Monday, August 19th, Zacks reports. Shareholders of record on Monday, September 16th will be paid a dividend of 1.55 per share by the medical instruments supplier on Monday, September 30th. This represents a $6.20 annualized dividend and a dividend yield of 0.79%. The ex-dividend date of this dividend is Friday, September 13th. This is a boost from Atrion’s previous quarterly dividend of $1.35.

Atrion has raised its dividend by an average of 15.6% per year over the last three years and has increased its dividend annually for the last 16 consecutive years.

Shares of ATRI stock traded up $0.75 during mid-day trading on Wednesday, hitting $786.45. The stock had a trading volume of 1,002 shares, compared to its average volume of 15,000. Atrion has a 12-month low of $624.00 and a 12-month high of $948.03. The firm has a market capitalization of $1.38 billion, a P/E ratio of 38.32 and a beta of 0.27. The firm’s 50-day moving average is $771.74 and its two-hundred day moving average is $832.81.

Atrion (NASDAQ:ATRI) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $5.18 earnings per share for the quarter. The business had revenue of $40.10 million during the quarter. Atrion had a return on equity of 16.79% and a net margin of 23.14%.

Several research analysts have recently commented on the company. BidaskClub raised Atrion from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 3rd. ValuEngine lowered Atrion from a “buy” rating to a “hold” rating in a research report on Friday, July 26th.

In other news, Director Ronald Nicholas Spaulding sold 200 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $903.00, for a total value of $180,600.00. Following the completion of the transaction, the director now directly owns 2,158 shares of the company’s stock, valued at approximately $1,948,674. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 22.07% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Read More: Day Trading – Risk Worth the Reward?

Dividend History for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with's FREE daily email newsletter.